SCHEMBL5841807

SCHEMBL5841807

CCOC(=O)c1cc2cc(CCC(=O)N3CCCC3)ccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.56
KDM4E B2RXH2 3/20 0.56
ALDH1A1 P00352 3/20 0.56
HPGD P15428 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
HSD17B10 Q99714 1/20 0.56
NPC1 O15118 3/20 0.53
LMNA P02545 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
HTT P42858 1/20 0.53
HRH3 Q9Y5N1 1/20 0.53
MMP13 P45452 7/20 0.52
MMP2 P08253 5/20 0.52
KMT2A Q03164 3/20 0.49
MMP14 P50281 3/20 0.49
MEN1 O00255 2/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
ATM Q13315 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5842347 0.83 KDM4E (0.65) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5843741 0.80 RAB9A (0.62) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL3560424 0.80 KDM4E (0.68) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL829242 0.80 KDM4E (0.76) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL10395119 0.79 KDM4E (0.67) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL7447241 0.79 KDM4E (0.67) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL27802281 0.78 KDM4E (0.65) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5842585 0.78 KDM4E (0.58) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL13174359 0.77 KDM4E (0.72) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL27518073 0.77 KDM4E (0.64) RAB9AKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071332-B2 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. (US) 2006-07-04 US disclosed
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2004-07-29 US disclosed
US-6706709-B2 TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER SUGEN, INC. 2004-03-16 US disclosed
EP-1294688-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2003-03-26 EP disclosed
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors SUGEN, INC. 2002-05-02 US disclosed
WO-2001094312-A2 INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147586-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 RAB9A 1352/4885KDM4E 948/4885ALDH1A1 2164/4885
US-20020052369-A1 Indolinone derivatives as protein kinase/phosphatase inhibitors PHKA1, PHKA2, PDPK1 RAB9A 1352/4885KDM4E 948/4885ALDH1A1 2164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.